☆ 4.6 Editorial Material

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy

EUROPEAN UROLOGY (2016)

Journal

EUROPEAN UROLOGY

Volume 69, Issue 1, Pages 4-6

Publisher

ELSEVIER SCIENCE BV

DOI: 10.1016/j.eururo.2015.10.017

Keywords

-

Categories

Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

Evolution of the HIF targeted therapy in clear cell renal cell carcinoma

Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega

Summary: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, and its pathogenesis is mainly caused by biallelic loss of the tumor suppressor gene VHL. Dysfunctional degradation of HIF due to VHL loss leads to overaccumulation of HIF, resulting in the activation of genes responsible for cell survival and proliferation in ccRCC. Previous therapies have targeted downstream effectors of HIF, but there is now a focus on interfering with upstream targets.

CANCER TREATMENT REVIEWS (2023)

Add to Collection

Review Oncology

Clear Cell Renal Cell Carcinoma: From Biology to Treatment

Adam M. Kase, Daniel J. George, Sundhar Ramalingam

Summary: Biological discoveries in the past two decades have revolutionized the treatment of renal cell carcinoma. The development of agents targeting pro-angiogenic pathways and immunogenicity have significantly impacted the management of clear cell renal cell carcinoma. Clear cell is the most common subtype, and therapies have focused on the Von Hippel Lindau gene alterations, leading to the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors. Combinations of these treatments have become the standard of care for advanced clear cell renal cell carcinoma, with promising new therapeutic targets under development.

CANCERS (2023)

Add to Collection

Review Urology & Nephrology

Outcomes of EAU-endorsed Live Surgical Events over a 5-year Period (2015-2020) and Updated Guidelines from the EAU Live Surgery Committee

Bhaskar Somani, Evangelos Liatsikos, Alexandre Mottrie, Ali S. Gozen, Alberto Breda, Thomas Knoll, Giampaolo Bianchi, Kemal Sarica, Jens Bedke, Jens Rassweiler

Summary: The study reviewed 5-year outcomes for live surgery events endorsed by the European Association of Urology, finding that the operations conducted at these events were safe and in compliance with previously set guidelines. Updated guidelines and new guidelines for semi-live events have been provided.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy

Johannes C. van der Mijn, Kenneth W. Eng, Pooja Chandra, Evan Fernandez, Sinan Ramazanoglu, Alexandros Sigaras, Clara Oromendia, Lorraine J. Gudas, Scott T. Tagawa, David M. Nanus, Bishoy F. Faltas, Himisha Beltran, Cora N. Sternberg, Olivier Elemento, Andrea Sboner, Juan Miguel Mosquera, Ana M. Molina

Summary: This study explored the genomic landscape of metastatic ccRCC and identified common gene mutations and copy number variations. The early appearance of certain CNVs may be associated with rapid clinical progression.

MOLECULAR ONCOLOGY (2022)

Add to Collection

Review Chemistry, Medicinal

Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma

Anne Laure Giraudet, Armelle Vinceneux, Valentin Pretet, Emilie Paquet, Alicia Sanchez Lajusticia, Fouzi Khayi, Jean Noel Badel, Helen Boyle, Aude Flechon, David Kryza

Summary: PSMA, highly expressed in metastatic aggressive prostate adenocarcinoma and neovessels of solid tumors, demonstrated an overall survival benefit in heavily pretreated metastatic prostate cancer in the VISION phase III trial. Despite advancements in managing metastatic clear cell renal cell carcinoma with antiangiogenic tyrosine kinase inhibitors and immunotherapy, there is still a need for new treatments. This study discusses the rationale of PSMA-targeted radioligand therapy in the treatment of metastatic clear cell renal cell carcinoma.

PHARMACEUTICALS (2023)

Add to Collection

Review Oncology

Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies

Valentina Schiavoni, Roberto Campagna, Valentina Pozzi, Monia Cecati, Giulio Milanese, Davide Sartini, Eleonora Salvolini, Andrea Benedetto Galosi, Monica Emanuelli

Summary: The aim of this review is to discuss novel prognostic and therapeutic markers for clear cell renal cell carcinoma (ccRCC), the most common variant of renal cell carcinoma. ccRCC is characterized by high aggressiveness, invasiveness, and metastatic potential, leading to poor prognosis and high mortality rate. This review provides an overview of the epidemiology, risk factors, established prognostic markers, and recent advances in treatment and biomarker discoveries for ccRCC.

CANCERS (2023)

Add to Collection

Article Immunology

Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma

Ganghua Zhang, Xinyu Chen, Jianing Fang, Panpan Tai, Aiyan Chen, Ke Cao

Summary: The development of immunotherapy has provided more treatment options for advanced kidney renal clear cell carcinoma (KIRC). This study explored the potential role of cuproptosis in KIRC and found that high cuproptosis score is associated with poor prognosis and low efficacy of immune checkpoint inhibitors, but high sensitivity to certain targeted drugs. Additionally, two potential cuproptosis-promoting genes were identified and cuproptosis was confirmed in KIRC cells.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Urology & Nephrology

European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

Richard J. Sylvester, Oscar Rodriguez, Virginia Hernandez, Diana Turturica, Lenka Bauerova, Harman Max Bruins, Johannes Bruendl, Theo H. van der Kwast, Antonin Brisuda, Jose Rubio-Briones, Maximilian Seles, Anouk E. Hentschel, Venkata R. M. Kusuma, Nicolai Huebner, Juliette Cotte, Laura S. Mertens, Dimitrios Volanis, Olivier Cussenot, Jose D. Subiela Henriquez, Enrique de la Pena, Francesca Pisano, Michael Pesl, Antoine G. van der Heijden, Sonja Herdegen, Alexandre R. Zlotta, Jaromir Hacek, Ana Calatrava, Sebastian Mannweiler, Judith Bosschieter, David Ashabere, Andrea Haitel, Jean-Francois Cote, Soha El Sheikh, Luca Lunelli, Ferran Algaba, Isabel Alemany, Francesco Soria, Willemien Runneboom, Johannes Breyer, Jakko A. Nieuwenhuijzen, Carlos Llorente, Luca Molinaro, Christina A. Hulsbergen-van de Kaa, Matthias Evert, Lambertus A. L. M. Kiemeney, James N'Dow, Karin Plass, Otakar Capoun, Viktor Soukup, Jose L. Dominguez-Escrig, Daniel Cohen, Joan Palou, Paolo Gontero, Maximilian Burger, Richard Zigeuner, Amir Hugh Mostafid, Shahrokh F. Shariat, Morgan Roupret, Eva M. Comperat, Marko Babjuk, Bas W. G. van Rhijn

Summary: This study updated the European Association of Urology prognostic factor risk groups for non-muscle-invasive bladder cancer, incorporating the WHO 2004/2016 and 1973 grading classifications and identifying a new very high-risk group. This can help urologists better tailor patients' treatment and follow-up plans.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Cell Biology

Ubiquitin Modification Patterns of Clear Cell Renal Cell Carcinoma and the Ubiquitin Score to Aid Immunotherapy and Targeted Therapy

Peng Zhou, Yuchao Lu, Yang Xun, Jinzhou Xu, Chenqian Liu, Qidong Xia, Junlin Lu, Shaogang Wang, Jia Hu

Summary: This study revealed the potential link between ubiquitin modification and the immune infiltration landscape of ccRCC for the first time, and provided a new assessment protocol for the precise selection of treatment strategies for patients with advanced ccRCC.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Oncology

Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights

Daniel Benamran, Laurence Albiges, Axel Bex, Gianluca Giannarini, Umberto Capitanio, Morgan Roupret

Summary: This article focuses on a 73-year-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma and treated with systemic therapy. It discusses current guideline-based treatment options, the role of cytoreductive nephrectomy and metastasis directed therapies in managing metastatic RCC, as well as various systemic targeted and immune therapies choices. Insights into future developments in treatment pathways are also provided.

EUROPEAN UROLOGY ONCOLOGY (2022)

Add to Collection

Review Oncology

Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade

Mathieu Larroquette, Felix Lefort, Luc Heraudet, Jean-Christophe Bernhard, Alain Ravaud, Charlotte Domblides, Marine Gross-Goupil

Summary: This article summarizes the main discoveries made in the treatment of metastatic clear cell renal cell carcinoma in recent years, including different generations of anti-VEGF targeted therapy drugs and immune checkpoint inhibitors (ICI), and provides an overview of the future developments in this field. The article also discusses new treatment approaches, such as escalation/de-escalation strategies, and introduces some potential new treatments to further improve patient survival.

CANCERS (2022)

Add to Collection

Article Oncology

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

Hanzhi Dong, Yuan Cao, Yan Jian, Jun Lei, Weimin Zhou, Xiaoling Yu, Xiquan Zhang, Zhiqiang Peng, Zhe Sun

Summary: This study analyzed the impact of nephrectomy on survival in patients with metastatic renal cell carcinoma who received immune-targeted therapy. The results showed that patients who underwent nephrectomy achieved survival benefits, and nephrectomy, clear cell carcinoma, and oligo-organ metastasis were found to be favorable independent prognostic factors.

BMC CANCER (2023)

Add to Collection

Article Oncology

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma

Scott J. Dawsey, Moshe C. Ornstein

Summary: Significant progress has been made in the treatment of metastatic renal cell carcinoma, with immunotherapy-based combinations becoming the standard of care. However, the effectiveness of salvage IO therapy in patients with disease progression on TKI monotherapy remains uncertain. Further clinical trials are needed to determine the clinical utility of salvage IO therapy in mRCC.

CURRENT ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Potential Application of Pyroptosis in Kidney Renal Clear Cell Carcinoma Immunotherapy and Targeted Therapy

Xiaochen Qi, Xiangyu Che, Quanlin Li, Qifei Wang, Guangzhen Wu

Summary: This study explores the feasibility of applying the pyroptosis mechanism to the clinical treatment of renal cell carcinoma (RCC), focusing on kidney renal clear cell carcinoma (KIRC). By analyzing genomic data and gene expression, clustering analysis, and prediction modeling, novel ideas and suggestions for the clinical treatment of KIRC are provided.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Urology & Nephrology

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma

Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H. Giles, Milan Hora, Thomas B. Lam, Borje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex

Summary: Recent trial data has shown a survival benefit with combination therapies of cabozantinib plus nivolumab, pembrolizumab plus axitinib, and ipilimumab plus nivolumab in advanced kidney cancer patients. These combinations are now recommended as first-line treatments for advanced kidney cancer.

EUROPEAN UROLOGY (2021)

Add to Collection

Editorial Material Urology & Nephrology

A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel

Umberto Capitanio, Jens Bedke, Laurence Albiges, Alessandro Volpe, Rachel H. Giles, Milan Hora, Lorenzo Marconi, Tobias Klatte, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Borje Ljungberg, Axel Bex

EUROPEAN UROLOGY (2023)

Add to Collection

Article Urology & Nephrology

The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma

Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H. Giles, Milan Hora, Borje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex

Summary: In the KEYNOTE-564 trial, adjuvant pembrolizumab showed significant improvement in disease-free survival (DFS) for localized clear-cell renal cell carcinoma (ccRCC) with a high risk of relapse. However, other immunotherapies, such as adjuvant atezolizumab, adjuvant nivolumab plus ipilimumab, and perioperative nivolumab did not meet the primary DFS endpoints. A meta-analysis is not recommended due to heterogeneity. Pembrolizumab remains the only recommended immune checkpoint inhibitor for this indication, but overall survival data are still immature and predictive biomarkers are lacking. Treatment decisions should be made cautiously and with patient involvement.

EUROPEAN UROLOGY (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal

Vasco Quaresma, Lorenzo Marconi, Roberto Jarimba, Joao Lima, Arnaldo Figueiredo

ACTA MEDICA PORTUGUESA (2023)

Add to Collection

Article Oncology

Assessment of Prostate Carcinoma Aggressiveness: Relation to 68Ga-PSMA-11-PET/MRI and Gleason Score

Jiri Ferda, Ondrej Hes, Milan Hora, Eva Ferdova, Jan Pernicky, Vladimir Rudnev, Ladislav Pecen, Ondrej Topolcan, Hynek Mirka

Summary: The uptake of 68Ga-PSMA-11 was found to be correlated with the expression of PSMA, and Gleason patterns 3 and 4 showed a higher correlation with the levels of 68Ga-PSMA-11. No or weak correlations were established with pharmacokinetic parameters.

ANTICANCER RESEARCH (2023)

Add to Collection

Article Oncology

Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience

Ondrej Fiala, Petr Hosek, Hana Korunkova, Milan Hora, Jiri Kolar, Jindra Windrichova, Ondrej Sorejs, Ondrej Topolcan, Ivan Travnicek, Hana Sedlackova, Jindrich Finek

Summary: This study retrospectively analyzed the long-term outcomes of 337 mCRPC patients treated with ENZ or AAP. The study confirmed the efficacy of both ENZ and AAP in mCRPC patients, and identified synchronous metastases, high GS, and visceral metastases as significant adverse prognostic factors.

ANTICANCER RESEARCH (2023)

Add to Collection

Letter Urology & Nephrology

A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel

Umberto Capitanio, Jens Bedke, Laurence Albiges, Alessandro Volpe, Rachel H. Giles, Milan Hora, Lorenzo Marconi, Tobias Klatte, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernandez Pello, Fabian Hofmann, Teele Kuusk, Riccardo Campi, Rana Tahbaz, Thomas Powles, Boerje Ljungberg, Axel Bex

EUROPEAN UROLOGY (2023)

Add to Collection

Article Urology & Nephrology

Predictive characteristics for disease recurrence and overall survival in non-metastatic clinical T1 renal cell carcinoma - results from the National Swedish Kidney Cancer Register

Tarik Almdalal, Andreas Karlsson Rosenblad, Mikael Hellstrom, Anders Kjellman, Per Lindblad, Sven Lundstam, Pernilla Sundqvist, Borje Ljungberg

Summary: This study examined the association between different treatments and disease recurrence as well as overall survival in patients with cT1RCC. The findings suggest that age, gender, tumor size, RCC type, and treatment modality are all factors associated with the risk of recurrence and overall survival. Patients with chRCC and those treated with PN had better overall survival compared to ccRCC patients and those treated with RN.

SCANDINAVIAN JOURNAL OF UROLOGY (2023)

Add to Collection

Article Nutrition & Dietetics

Dietary vitamin D intake and the bladder cancer risk: A pooled analysis of prospective cohort studies

Iris W. A. Boot, Anke Wesselius, Evan Y. W. Yu, Emily White, Margritt Brustad, Chloe Marques, Borje Ljungberg, Maurice P. Zeegers

Summary: This study investigated the relationship between vitamin D intake and bladder cancer risk. The results showed that high intake of vitamin D combined with low intake of calcium and moderate intake of phosphorus is associated with a decreased risk of bladder cancer.

CLINICAL NUTRITION (2023)

Add to Collection

Article Medicine, Research & Experimental

Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma

Andre Mansinho, Andreia Cruz, Lorenzo Marconi, Cidalia Pinto, Isabel Augusto

Summary: This work provides a summary of guideline recommendations and an expert position on the use of maintenance avelumab therapy for locally advanced or metastatic urothelial carcinoma (UC) based on a review of current international clinical practice guidelines. The expert panel recommends maintenance avelumab therapy in patients with response/stable disease following chemotherapy (regardless of PD-L1 status) for locally advanced or metastatic UC.

ADVANCES IN THERAPY (2023)

Add to Collection

Article Urology & Nephrology

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups

Lorenzo Marconi, Teele Kuusk, Umberto Capitanio, Christian Beisland, Thomas Lam, Sergio Fernandez Pello, Grant D. Stewart, Tobias Klatte, Alessandro Volpe, Borje Ljungberg, Saeed Dabestani, Axel Bex

Summary: This study evaluated the effectiveness of local treatment for resectable recurrent renal cell carcinoma after surgical treatment of the primary kidney tumor. The results showed that local treatment could improve patients' survival, regardless of the risk of recurrence.

EUROPEAN UROLOGY OPEN SCIENCE (2023)

Add to Collection

Review Urology & Nephrology

A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer

Katharina Beyer, Christiaan Widdershoven, Lisa M. Wintner, Saeed Dabestani, Lorenzo Marconi, Charlotte Moss, Netty Kinsella, Yuhong Yuan, Rachel H. Giles, Ravi Barod, Mieke Van Hemelrijck, Axel Bex, Patricia Zondervan, Steven MacLennan

Summary: This study investigates the heterogeneity in outcome reporting in effectiveness trials and observational studies in localized renal cell carcinoma. The results show inconsistency in outcome reporting across studies and variability in definitions for conceptually similar outcomes.

EUROPEAN UROLOGY OPEN SCIENCE (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.